Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Sodium Glycerophosphate vs Sodium Phosphate
NCT06842121Phase 1Completed
- Sponsor
- Baxter
- Start
- Jan 2025
- Primary completion
- May 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of sodium glycerophosphate in hypophosphatemia (2 arms), sponsored by Baxter. Primary endpoints: Baseline-corrected Maximum Observed Concentration for Inorganic Phosphate at Day 8 and Baseline-corrected Area Under the Curve for Inorganic Phosphate at Day 8. Started Jan 2025; status: completed.
02
Drugs
sodium glycerophosphate
03
Conditions
hypophosphatemia
Beyond the preview
Go deeper on NCT06842121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06842121.